A Syrian scientist has found a new method for cancer treatment by stimulating the immune system, which reduces the need for chemotherapy or surgical interventions. This new treatment is called "alkaline keferan" or "sugar bomb," developed by lab sciences specialist Ibrahim Al-Sha'ar and his team, aimed at achieving positive results against lung cancer, breast cancer, and sarcoma (a rare type of tumor affecting connective tissues such as muscle, fat, nerves, or blood vessels).
Al-Sha'ar explains that "cancer tumors have the ability to halt the immune system, leading to chemotherapy failure, and they also disrupt programmed cell death mechanisms (for renewal purposes)." The new treatment reveals these cells to the immune system so it can deal with them through what is known as "targeted metabolism," a method of smart therapy.
In an interview with "Sky News Arabia," he added that the "sugar bomb" method works to reactivate the immune system to recognize and destroy cancer tumors without affecting healthy cells, while using energy to kill cancer cells from within. He noted that "cancer cells create channels to ensure blood supply to them, which the treatment aims to prevent, leading to cell death."
Al-Sha'ar states that his studies have been conducted on cases of breast cancer, lung cancer, and sarcoma, which are extremely difficult cases often unresponsive to chemotherapy. He mentioned that the research team is currently in the third phase of clinical trials, which have been conducted on 700 cases, some of which were hopeless, and the treatment has proven effective in 70 percent of those cases. The results of these trials will be published soon.
Regarding the commercialization of the innovation, he indicated that "the treatment goes through five phases of clinical studies, and the research team has completed the third phase. We will publish the results in peer-reviewed scientific journals before global companies adopt this invention in its final stages, applying it to larger samples, monitoring results, statistical studies, and obtaining the necessary licenses for drug production."
He noted that the innovative treatment can be taken after completing chemotherapy or surgical treatment to reduce the chances of disease recurrence and can be administered from the start to those who refuse chemotherapy, which is a better approach as it can help avoid surgeries in breast cancer patients. As for the treatment's side effects, Al-Sha'ar mentions that they are "mild and limited in consequences," pointing out that the treatment reveals how cancer cells evade immune therapy.
